Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses the efficacy and safety of the CD19 targeted chimeric antigen receptor (CAR) T-cells in relapsed B-cell acute lymphoblastic leukemia (ALL) adult patients. CAR T-cells are the patient’s own T-cells which have been genetically engineered to express a chimeric antigen receptors that’s engineered to target a specific tumour antigens, in this case CD19. A phase I clinical trial has been conducted on 51 subjects, and has had positive results. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
EHA 2016: Current research on CD19 targeted CAR T-cells in relapsed B-cell ALL
